Oxidative Medicine and Cellular Longevity
Volume 2019 (2019), Article ID 9601435, 1 page
https://doi.org/10.1155/2019/9601435

Corrigendum

Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”

Stefania Gorini,¹ Antonella De Angelis,² Liberato Berrino,² Natalia Malara,³ Giuseppe Rosano,1,4 and Elisabetta Ferraro¹

¹Laboratory of Pathophysiology of Cachexia and Metabolism of Skeletal Muscle, IRCCS San Raffaele Pisana, 00166 Rome, Italy
²Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
³Bionem Laboratory, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy
⁴Cardiovascular and Cell Sciences Institute, St George’s, University of London, Cranmer Terrace, London, UK

Correspondence should be addressed to Elisabetta Ferraro; elisabetta.ferraro@sanraffaele.it

Received 21 February 2019; Accepted 24 February 2019; Published 26 June 2019

Copyright © 2019 Stefania Gorini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib” [1], the author Giuseppe Rosano should have been affiliated to the first and fourth affiliations. The corrected authors’ list is shown above.

References

S. Gorini, A. De Angelis, L. Berrino, N. Malara, G. Rosano, and E. Ferraro, “Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 7582730, 15 pages, 2018.